We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 384

Complex proceedings may justify an award at the high end of Column IV, but not a further increase
  • Borden Ladner Gervais LLP
  • Canada
  • November 23 2016

Hospira brought a motion seeking directions concerning the assessment of its costs in the underlying proceeding. The Court agreed with the parties


An unsuccessful defendant is not entitled to elect an accounting of profits to shield itself from an award of damages
  • Borden Ladner Gervais LLP
  • Canada
  • November 9 2016

On September 7, 2016, the Court held that Bayer's patent was valid and infringed (2016 FC 1013; our summary here). The parties were given an


Appeal relating to double patenting and sufficiency of tadalafil patent dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • November 9 2016

The Federal Court of Appeal considered an appeal from Apotex relating to double patenting and insufficiency of a patent claiming the use of tadalafil


Amendments allowing a new defence of anticipation and issue estoppel are allowed in part
  • Borden Ladner Gervais LLP
  • Canada
  • October 26 2016

The Federal Court has allowed Apotex to amend its statement of defence to include a new anticipation claim and a new defence of issue estoppel and


Supreme Court Updates
  • Borden Ladner Gervais LLP
  • Canada
  • October 26 2016

The Federal Court has allowed Apotex to amend its statement of defence to include a new anticipation claim and a new defence of issue estoppel and


Patent anticipated by hearsay documents that met the test of necessity due to failure to comply with Federal Courts Rules
  • Borden Ladner Gervais LLP
  • Canada
  • October 26 2016

The Federal Court dismissed Gilead's application for prohibition in respect to the combination drug TUVADA covered in the '475 Patent. This


Cross-licensing agreements held to not trigger the requirement to send a Notice of Allegation under the PM(NOC) Regulations
  • Borden Ladner Gervais LLP
  • Canada
  • October 19 2016

The Federal Court of Appeal has overturned two decisions of the Federal Court, relating to the issuance of an NOC to a generic company who did not


Plaintiff granted summary judgment for unpaid royalties
  • Borden Ladner Gervais LLP
  • Canada
  • October 19 2016

The Ontario Court granted the Plaintiff's motion for summary judgment for payment of royalties owing under the licence agreement. The inventor, Arnold


Patent found not to be infringed following construction of the term "independently"
  • Borden Ladner Gervais LLP
  • Canada
  • October 19 2016

Cascade is the owner of a Canadian patent related to a safety locking device for quick couplers and claims that Kinshofer have infringed or induced


Court Grants Order Correcting Inventorship, but Declines to Order Recording of Documents at Patent Office
  • Borden Ladner Gervais LLP
  • Canada
  • October 12 2016

Qualcomm sought an order pursuant to s. 52 of the Patent Act to add Mr. Rychlik as the sole inventor and to remove two of the named inventors. The